1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Biosimilars and Follow-on Biologics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Incentivizing Providers to Adopt Biosimilars
3.2.1.2 Developed Regions Driving the Worldwide Biosimilars and Follow-on Biologics Market Growth
3.2.1.3 Biologics Patent Expiry Set to Open Fresh Revenue Pockets for Biosimilars Companies Over the Next Decade
3.2.1.4 Pricing Advantage of Biosimilars Comparison to Biologics Anticipated to Fuel Market Growth
3.2.2 Market Restraining Factors
3.2.2.1 High Cost Involvement, Uncertainty and Complexities in Manufacturing
3.2.2.2 Resistance from Biologics Manufacturers to Restrain Market Growth
3.2.2.3 Reluctance of Healthcare Providers to Switch to Biosimilars
3.2.3 Market Opportunities
3.2.3.1 Companies Can Use Information of Original Innovator thus Shorten Development & Approval Processes
3.2.3.2 Diversity in Approach Among the Authorities
3.3 Trends
3.3.1 Regulatory Hurdles Slowing Down Access to Biosimilars
3.3.2 Vulnerability of Global Pharmaceutical Manufacturing Amid COVID-19
3.3.3 Emerging Economies Continues to Pose Challenges for Building Presence for Generics and Biosimilars Companies
3.3.4 Digital Transformations as a Key Enabler to Strengthen Research in Biosimilars Industry
3.4 COVID-19 Impact Analysis
3.5 Porter’s Five Forces Analysis
3.5.1 Supplier Power
3.5.2 Buyer Power
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis
3.6.1 Political Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.2 Economic Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.3 Social Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.4 Technological Factors Impacting Biosimilars and Follow-on Biologics Market
4 Biosimilars and Follow-on Biologics Market Analysis by Type of Manufacturing
4.1 Key Findings
4.2 Type of Manufacturing Segment: Market Attractiveness Index
4.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Type of Manufacturing
4.4 In-House
4.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 CMOs
4.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.5.2 Market Share by Region, 2023 & 2033 (%)
5 Biosimilars and Follow-on Biologics Market Analysis by Type
5.1 Key Findings
5.2 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Type
5.3 Monoclonal Antibodies
5.3.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.3.2 Market Share by Region, 2023 & 2033 (%)
5.4 Fusion Proteins
5.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Insulin
5.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Erythropoietin
5.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Granulocyte-Colony Stimulating Factor
5.7.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 Interferon
5.8.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.8.2 Market Share by Region, 2023 & 2033 (%)
5.9 Growth Hormones
5.9.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.9.2 Market Share by Region, 2023 & 2033 (%)
5.10 Fertility Hormones
5.10.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.10.2 Market Share by Region, 2023 & 2033 (%)
5.11 Others
5.11.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.11.2 Market Share by Region, 2023 & 2033 (%)
6 Biosimilars and Follow-on Biologics Market Analysis by Application
6.1 Key Findings
6.2 Application Segment: Market Attractiveness Index
6.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Application
6.4 Blood Disorders
6.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Oncology Diseases
6.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Chronic & Autoimmune Diseases
6.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.6.2 Market Share by Region, 2023 & 2033 (%)
6.7 Growth Hormone Deficiencies
6.7.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.7.2 Market Share by Region, 2023 & 2033 (%)
6.8 Others
6.8.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.8.2 Market Share by Region, 2023 & 2033 (%)
7 Biosimilars and Follow-on Biologics Market Analysis by Technology
7.1 Key Findings
7.2 Technology Segment: Market Attractiveness Index
7.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Technology
7.4 rDNA Technology
7.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.5 mAbs Technology
7.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
7.5.2 Market Share by Region, 2023 & 2033 (%)
7.6 Bioassay Technology
7.6.1.1 Chromatography
7.6.1.2 Mass Spectrometry
7.6.1.3 NMR (Nuclear Magnetic Resonance)
7.6.1.4 Electrophoresis
7.6.2 Market Forecast by Region, 2023-2033 (US$ Mn)
7.6.3 Market Share by Region, 2023 & 2033 (%)
8 Biosimilars and Follow-on Biologics Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Biosimilars and Follow-on Biologics Market Analysis
9.1 Key Findings
9.2 North America Biosimilars and Follow-on Biologics Market Attractiveness Index
9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
9.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
9.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
9.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
9.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
9.9 U.S.
9.9.1 United States is Just Beginning to Catch Up European Biosimilars Market
9.9.2 Rising Biosimilar Uptake to Fuel U.S. Biosimilars Market Growth
9.9.3 Advancements in Biosimilars Development and Approvals Across the United States to Fuel Market Growth
9.10 Canada
9.10.1 Biosimilar Authorization Activity Across Canadian Region
9.10.2 Initiatives by Health Canada to Boost Canadian Biosimilars and Follow-on Biologics Market Over the Next Decade
9.10.3 Availability of Biosimilars in Oncology Treatment Landscape Driving Regional Growth
9.10.4 Canada Biosimilars and Follow-on Biologics Market Outlook
10 Europe Biosimilars and Follow-on Biologics Market Analysis
10.1 Key Findings
10.2 Growing Prevalence of Lifestyle Diseases Anticipated to Fuel European Biosimilars Market Growth
10.3 Continued Benefits of Biosimilars to Offer Lucrative Growth Prospects in Long Term
10.4 Europe Biosimilars and Follow-on Biologics Market Attractiveness Index
10.5 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
10.6 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
10.7 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
10.8 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
10.9 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
10.10 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
10.11 Germany
10.11.1 Biosimilars Have Been Accepted as an Important Component of Proper Medication Usage in Germany
10.11.2 Germany Intends to Switch to Biologics Pharmacies by August 2022 thus Jeopardising the Long-Term Viability of Biosimilars
10.11.3 Germany Biosimilars and Follow-on Biologics Market Outlook
10.12 UK
10.12.1 NHS Encouraging the Growth of Biosimilar Manufacturing in United Kingdom
10.12.2 Despite Price Reduction, Biosimilar Medications are not Widely Used in Retail Settings
10.12.3 UK Biosimilars and Follow-on Biologics Market Outlook
10.13 France
10.14 Italy
10.14.1 Italian Government Policies Anticipated to Fuel Development of Biosimilars Market Across the Region
10.14.2 Biosimilars to Help Reduce Price of Pharmaceuticals Across the Italian Region
10.15 Spain
10.15.1 Budget Impact Analysis of Biosimilar Products in Spain
10.16 Rest of Europe
11 Asia Pacific Biosimilars and Follow-on Biologics Market Analysis
11.1 Key Findings
11.2 Low Clinical Development Costs Coupled with Regulatory Framework Ease to Fuel Regional Growth
11.3 Indian Pharmaceutical Companies Have an Enormous Scope in the Biosimilars Market
11.4 Asia Pacific Biosimilars and Follow-on Biologics Market Attractiveness Index
11.5 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
11.6 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
11.7 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
11.8 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
11.9 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
11.10 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
11.11 Japan
11.11.1 Biosimilars to Bolster Japanese Healthcare System Growth Over the Next Decade
11.11.2 Japan still has a slow growth in this sector compared to US and EU
11.11.3 Introduction of Biosimilars to Boost Regional Growth
11.11.4 Ageing Japanese Population Demanding the Development of Biosimilars Over the Forecast Period
11.12 China
11.12.1 Significant Surge in Biosimilar Approvals to Drive Market Growth
11.12.2 Technological Advancements to Fuel Chinese Biosimilars Market Growth Over the Forecast Period
11.12.3 Expansion by Major Firms to Boost Chinese Biosimilars Market Growth
11.12.4 Overcrowding of Chinese Market Has Led to the Withdrawal of International Players
11.13 India
11.13.1 India Set to Become Sixth Largest Pharmaceutical Market By End of 2030
11.13.2 Renowned Pharmaceutical Companies Establishing Partnerships with Indian Pharma Companies
11.13.3 India Biosimilars and Follow-on Biologics Market Outlook
11.14 Rest of Asia Pacific
12 Latin America Biosimilars and Follow-on Biologics Market Analysis
12.1 Key Findings
12.2 Latin America Biosimilars and Follow-on Biologics Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
12.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
12.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
12.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
12.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
12.9 Brazil
12.9.1 Brazilian Biosimilars Regulations
12.10 Mexico
12.11 Rest of Latin America
13 MEA Biosimilars and Follow-on Biologics Market Analysis
13.1 Key Findings
13.2 MEA Biosimilars and Follow-on Biologics Market Attractiveness Index
13.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
13.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
13.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
13.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
13.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
13.9 GCC
13.9.1 GCC Gearing Up to Take Big Jump on Biosimilars
13.9.2 Collaborations Among Pharmaceutical Firms Across GCC to Offer Lucrative Growth Prospects for Market Players Over the Forecast Period
13.10 South Africa
13.10.1 South African Evolving Demographic and Epidemiological Profile to Offer Lucrative Growth Prospects
13.10.2 Presence of Major Pharmaceutical Firms to Intensify Competition
13.11 Rest of MEA
14 Company Profiles
14.1 3SBio, Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Product Benchmarking
14.1.4 Strategic Outlook
14.2 AMEGA Biotech
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Product Benchmarking
14.3 Amgen Inc.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2015-2021
14.3.3.2 R&D Expenses, 2015-2021
14.3.3.3 Gross Profit, 2015-2021
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Apotex, Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Product Benchmarking
14.5 BIOCAD
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Product Benchmarking
14.5.4 Strategic Outlook
14.6 Biocon Limited
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2017-2021
14.6.3.2 R&D Expenses, 2017-2021
14.6.3.3 Biosimilars Sales, 2017-2021
14.6.3.4 Business Segment Market Share, 2021
14.6.3.5 Geographic Market Share, 2021
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Biogen, Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Product Benchmarking
14.8 Celltrion Healthcare Co.,Ltd.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.8.4 Strategic Outlook
14.9 Coherus BioSciences
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Product Benchmarking
14.9.4 Strategic Outlook
14.10 Dr. Reddy’s Laboratories Ltd.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Product Benchmarking
14.11 Eli Lilly and Company
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2015-2021
14.11.3.2 R&D Expenses, 2015-2021
14.11.3.3 Gross Profit, 2015-2021
14.11.3.4 Geographic Revenue, 2018-2021
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Gedeon Richter PLC
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Product Benchmarking
14.12.4 Strategic Outlook
14.13 Intas Pharmaceutical Ltd.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.14 Mabxience SA
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Viatris Inc. (Mylan NV)
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2015-2021
14.15.3.2 R&D Expenses, 2015-2021
14.15.3.3 Gross Profit, 2015-2021
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Novartis AG
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2015-2021
14.16.3.2 R&D Expenses, 2015-2021
14.16.3.3 Gross Profit, 2015-2021
14.16.3.4 Net Sales by Business Segment, 2019-2021
14.16.3.5 Net sales to third parties by business franchise in the Sandoz Division, 2020
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 Pfizer Inc.
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.3.1 Net Revenue, 2015-2021
14.17.3.2 R&D Expenses, 2015-2021
14.17.3.3 Gross Profit, 2015-2021
14.17.3.4 Geographic Market Share, 2021
14.17.4 Product Benchmarking
14.17.5 Strategic Outlook
14.18 Samsung Bioepis Co. Ltd.
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Product Benchmarking
14.18.4 Strategic Outlook
14.19 Stada Arzneimittel AG
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2016-2020
14.19.3.2 Gross Profit, 2016-2020
14.19.3.3 Net Sales by Segment, 2019-2020
14.19.4 Product Benchmarking
14.19.5 Strategic Outlook
14.20 Teva Pharmaceutical
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Financial Analysis
14.20.3.1 Net Revenue, 2015-2021
14.20.3.2 R&D Expenses, 2015-2021
14.20.3.3 Gross Profit, 2015-2021
14.20.4 Product Benchmarking
15 Conclusion and Recommendations
15.1 Concluding Remarks from
15.2 Recommendations for Market Players